Drug intelligence / Profile preview

lisinopril

Development stage: Approved
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure (hypertension), heart failure, and to improve survival after a heart attack. It is also used to prevent kidney problems in people with diabetes mellitus. Lisinopril works by inhibiting the renin–angiotensin–aldosterone system, specifically blocking the conversion of angiotensin I to angiotensin II, a substance that narrows blood vessels. By reducing levels of angiotensin II, lisinopril relaxes blood vessels and lowers blood pressure, making it easier for the heart to pump blood[1][5][7]. Lisinopril was patented in 1978 and approved for medical use in 1987[5].

Brand names: PrinivilZestrilQbrelis
Other names: lisinopril anhydrouslisinopril dihydrate

Targets

ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on lisinopril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lisinopril.

Explore the full profile